CH0027148649
© Globe Newswire
15.01.2026
SANN
LISTED
SIX
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
News Preview
Commercial launch in Switzerland anticipated in H2 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.01.2026
SANN
LISTED
SIX
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
SANN
LISTED
SIX
Santhera Closes USD 13 Million Royalty Monetization Agreement
News Preview
Pratteln, Switzerland, November 5, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, to support the global launches of AGAMREE® (vamorolone)....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
04.11.2025
SANN
LISTED
SIX
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
04.11.2025
SANN
LISTED
SIX
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
News Preview
Pratteln, Switzerland, November 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today reported positive topline results from an analysis of long-term data, including first assessments from the ongoing, open-label, multicenter GUARDIAN study evaluating AGAMREE® (vamorolone) in patients with Duchenne muscular dystrophy (DMD)....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2025
SANN
LISTED
SIX
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia
News Preview
Pratteln, Switzerland, October 9, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® (vamorolone) in Russia, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older....
Themefolio
Profiler
Peergroup
© Globe Newswire
03.10.2025
SANN
LISTED
SIX
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
News Preview
Pratteln, Switzerland, October 3, 2025 – Santhera Pharmaceuticals (SIX: SANN) today notes that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older following Priority Review, marking the first approved treatment for the disease in Canada. The Canadian Neuromuscula...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.09.2025
SANN
LISTED
SIX
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
SANN
LISTED
SIX
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
SANN
LISTED
SIX
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.09.2025
SANN
LISTED
SIX
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2025
SANN
LISTED
SIX
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
News Preview
Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older....
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
19.08.2025
SANN
LISTED
SIX
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
News Preview
Pratteln, Switzerland, 19 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia, Kuwait, Oman and Bahrain, for the treatment of Duchenne muscular dystrophy (DMD) in patients four yea...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2025
SANN
LISTED
SIX
Santhera extends Highbridge convertible bond to 30th September 2025
News Preview
Ad hoc announcement pursuant to Art. 53 LRA...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2025
SANN
LISTED
SIX
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
News Preview
Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.05.2025
SANN
LISTED
SIX
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
News Preview
Pratteln, Switzerland, May 20, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 5,073,050 shares or 37.5% of the Company’s s...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.04.2025
SANN
LISTED
SIX
Santhera Publishes Agenda for its Annual General Meeting
News Preview
Pratteln, Switzerland, April 29, 2025 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 20, 2025, at 10:00 CEST at Haus der Wirtschaft, Hardstrasse 1, 4133 Pratteln, Switzerland....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.04.2025
SANN
LISTED
SIX
Santhera shares updates on commercial rollout of AGAMREE®
News Preview
Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD)....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
SANN
LISTED
SIX
Santhera proposes Dr. Melanie Rolli as new member of Board of Directors
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
SANN
LISTED
SIX
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
News Preview
Pratteln, Switzerland, March 24, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the treatment of Duchenne Muscular Dystropy (DMD). The Company will also outline plans for further market expansion an...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.03.2025
SANN
LISTED
SIX
Full Year Trading Update
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.02.2025
SANN
LISTED
SIX
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.02.2025
SANN
LISTED
SIX
Santhera Announces Chief Financial Officer Transition with Appointment of Catherine Isted
News Preview
Pratteln, Switzerland, February 10, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Catherine Isted as Chief Financial Officer (CFO), effective February 24, 2025. She succeeds Andrew Smith, who, after five years at Santhera and financially securing the stable foundations of the company, has decided to step down. He will rem...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2025
SANN
LISTED
SIX
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
News Preview
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends AGAMREE® (vamorolone) for use in the National Health Service (NHS) in England, Wales and Northern Ireland for the treatment of Duchenne muscular...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2025
SANN
LISTED
SIX
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
News Preview
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently exercised outstanding warrants held in Santhera on a cashless basis, reinforcing its...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.01.2025
SANN
LISTED
SIX
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
News Preview
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2025
SANN
LISTED
SIX
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
News Preview
Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product is not otherwise commercially available....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
SANN
LISTED
SIX
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
News Preview
Pratteln, Switzerland, December 20, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older....
Themefolio
Profiler
Peergroup
© Globe Newswire
11.12.2024
SANN
LISTED
SIX
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
News Preview
Pratteln, Switzerland, December 11, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that China’s National Medical Products Administration (NMPA) has approved AGAMREE® (vamorolone) for use in China in patients aged 4 years and older....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2024
SANN
LISTED
SIX
Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
News Preview
Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2024
SANN
LISTED
SIX
Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar
News Preview
Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of patients with Duchenne muscular dystrophy (DMD) with AGAMREE under a Named Patient Program....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2024
SANN
LISTED
SIX
Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism
News Preview
Pratteln, Switzerland, October 1, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the positive outcome of the LIONHEART study, confirming vamorolone’s distinctive action also as a mineralocorticoid receptor antagonist, setting it apart from other corticosteroids....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.09.2024
SANN
LISTED
SIX
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
News Preview
Pratteln, Switzerland, September 24, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that Swissmedic, the Swiss Agency for Therapeutic Products, has accepted for review the marketing authorization application (MAA) for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD)....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.09.2024
SANN
LISTED
SIX
Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2024
SANN
LISTED
SIX
Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe
News Preview
Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in 20 markets in Central and Eastern Europe....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.08.2024
SANN
LISTED
SIX
Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2024
SANN
LISTED
SIX
Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary
News Preview
Pratteln, Switzerland, July 31, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the Board of Directors has appointed Dr. Oliver P. Kronenberg as Chief Legal Officer and Corporate Secretary of Santhera Pharmaceuticals AG, effective August 1, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
18.06.2024
SANN
LISTED
SIX
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2024
SANN
LISTED
SIX
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix
News Preview
Pratteln, Switzerland, June 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for AGAMREE® (vamorolone) in China for patients with Duchenne muscular dystrophy (DMD)....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
SANN
LISTED
SIX
Santhera Publishes Agenda for its Annual General Meeting
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.05.2024
SANN
LISTED
SIX
Santhera Publishes Annual Report 2023
News Preview
Ad hoc announcement pursuant to Art. 53 LR...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
